Retraction to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. [Mol Cancer. 12, (2013) (34)] DOI: 10.1186/1476-4598-12-34;Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Perez White, Bethany ^a   Molloy, Mary Ellen ^a   Zhao, Huiping ^a   Zhang, Yiyun ^b   Tonetti, Debra A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Extranuclear ER ; PKC ; Raloxifene; Tamoxifen

Indexed keywords

CAVEOLIN 1; ESTROGEN RECEPTOR ALPHA; MATRIGEL; PROTEIN KINASE C ALPHA; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE OVEREXPRESSION; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TUMOR REGRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

MUS;

EID: 84876795226     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-017-0697-5     Document Type: Erratum

References (55)

1. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62:233-247. 10.1146/annurev-med-070909-182917, 20887199.
2. Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer 2003, 88:1400-1402. 10.1038/sj.bjc.6600923, 2741052, 12778068.
3. Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 2007, 60:1216-1221. 10.1136/jcp.2006.041616, 2095478, 17965220.
4. Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer 2010, 9:76. 10.1186/1476-4598-9-76, 2873434, 20398285.
5. Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 2000, 83:782-791. 10.1054/bjoc.2000.1326, 2363523, 10952784.
6. Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti D. Overexpression of PKCα is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis 2006, 27:1538-1546.
7. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 2001, 7:3156-3165.
8. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000, 6:2028-2036.
9. Zhang Y, Zhao H, Asztalos S, Chisamore M, Sitabkhan Y, Tonetti DA. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res 2009, 7:498-510. 10.1158/1541-7786.MCR-08-0415, 2743931, 19372579.
10. Nemere I, Farach-Carson MC. Membrane receptors for steroid hormones: a case for specific cell surface binding sites for vitamin D metabolites and estrogens. Biochem Biophys Res Commun 1998, 248:443-449. 10.1006/bbrc.1998.8492, 9703943.
11. Watson CS, Gametchu B. Membrane-initiated steroid actions and the proteins that mediate them. Proc Soc Exp Biol Med 1999, 220:9-19. 10.1046/j.1525-1373.1999.d01-2.x, 9893163.
12. Molloy CA, May FE, Westley BR. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 2000, 275:12565-12571. 10.1074/jbc.275.17.12565, 10777546.
13. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407:538-541. 10.1038/35035131, 2670482, 11029009.
14. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003, 17:818-830. 10.1210/me.2002-0330, 12554767.
15. Kelly MJ, Levin ER. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 2001, 12:152-156. 10.1016/S1043-2760(01)00377-0, 11295570.
16. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 2002, 16:116-127. 10.1210/me.16.1.116, 11773443.
17. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 2001, 20:6050-6059. 10.1093/emboj/20.21.6050, 125704, 11689445.
18. Marquez DC, Pietras RJ. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001, 20:5420-5430. 10.1038/sj.onc.1204729, 11571639.
19. Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, Stoica A. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003, 22:7998-8011. 10.1038/sj.onc.1206769, 12970748.
20. Nicholson RI, Johnston SR. Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat 2005, 93(Suppl 1):S3-S10.
21. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 2005, 56(Suppl 1):10-20.
22. Song RX, Chen Y, Zhang Z, Bao Y, Yue W, Wang JP, Fan P, Santen RJ. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol 2010, 118:219-230. 10.1016/j.jsbmb.2009.09.018, 2826506, 19815064.
23. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009, 302:774-780. 10.1001/jama.2009.1204, 3460383, 19690310.
24. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001, 67:111-116. 10.1023/A:1010619225209, 11519859.
25. Nardulli AM, Katzenellenbogen BS. Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo. Endocrinology 1986, 119:2038-2046. 10.1210/endo-119-5-2038, 3533520.
26. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003, 11:695-707. 10.1016/S1097-2765(03)00090-X, 12667452.
27. Seo HS, Larsimont D, Querton G, El Khissiin A, Laios I, Legros N, Leclercq G. Estrogenic and anti-estrogenic regulation of estrogen receptor in MCF-7 breast-cancer cells: comparison of immunocytochemical data with biochemical measurements. Int J Cancer 1998, 78:760-765.
28. Wijayaratne AL, McDonnell DP. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001, 276:35684-35692. 10.1074/jbc.M101097200, 11473106.
29. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A 2004, 101:2076-2081. 10.1073/pnas.0308334100, 357054, 14764897.
30. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 2003, 23:1633-1646. 10.1128/MCB.23.5.1633-1646.2003, 151696, 12588983.
31. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol Biol Cell 2005, 16:231-237. 539167, 15496458.
32. O'Brian C. Elevated protein kinase C expression in human breast tumor biopsies relative to normal tissue. Cancer Res 1989, 49:3215-3217.
33. Lahn M, Köhler G, Sundell K, Su C, Li S, Paterson BM, Bumol TF. Protein kinase C alpha expression in breast and ovarian cancer. Oncology 2004, 67:1-10.
34. Ali S, Al-Sukhun S, El-Rayes BF, Sarkar FH, Heilbrun LK, Philip PA. Protein kinases C isozymes are differentially expressed in human breast carcinomas. Life Sci 2009, 84:766-771. 10.1016/j.lfs.2009.03.007, 19324060.
35. Ainsworth PD, Winstanley JH, Pearson JM, Bishop HM, Garrod DR. Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma. Eur J Cancer 2004, 40:2269-2273. 10.1016/j.ejca.2004.06.027, 15454252.
36. Kerfoot C, Huang W, Rotenberg SA. Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J Histochem Cytochem 2004, 52:419-422. 10.1177/002215540405200314, 14966210.
37. Tonetti DA, Gao W, Escarzaga D, Walters K, Szafran A, Coon JS. PKC alpha; and ER beta; are associated with triple-negative breast cancers in African American and Caucasian patients. Int J Breast Cancer 2012, 2012.
38. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996, 15:1292-1300. 450032, 8635462.
39. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104:719-730.
40. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, Simoncini T. Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One 2008, 3:e2238. 10.1371/journal.pone.0002238, 2375059, 18493596.
41. Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A, Agyin JK, Brann D, Sun LZ, Yeh IT. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res 2010, 70:4092-4101. 10.1158/0008-5472.CAN-09-3834, 2889925, 20460518.
42. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 2002, 418:654-657. 10.1038/nature00889, 12167865.
43. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004, 10:3621-3628. 10.1158/1078-0432.CCR-0740-3, 15173068.
44. Fan P, Wang J, Santen RJ, Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 2007, 67:1352-1360. 10.1158/0008-5472.CAN-06-1020, 17283173.
45. Newton AC. Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab 2009, 298:E395-E402. 2838521, 19934406.
46. Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 2008, 108:351-361. 10.1007/s10549-007-9618-4, 17592774.
47. Gutierrez S, Sosa L, Petiti JP, Mukdsi JH, Mascanfroni ID, Pellizas CG, De Paul AL, Cambiasso MJ, Torres AI. 17beta-Estradiol stimulates the translocation of endogenous estrogen receptor alpha at the plasma membrane of normal anterior pituitary cells. Mol Cell Endocrinol 2012, 355:169-179. 10.1016/j.mce.2012.02.008, 22366173.
48. Yudt MR, Vorojeikina D, Zhong L, Skafar DF, Sasson S, Gasiewicz TA, Notides AC. Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation. Biochemistry 1999, 38:14146-14156. 10.1021/bi9911132, 10571988.
49. Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 2006, 25:3286-3295. 10.1038/sj.onc.1209361, 16407820.
50. Longo M, Brama M, Marino M, Bernardini S, Korach KS, Wetsel WC, Scandurra R, Faraggiana T, Spera G, Baron R. Interaction of estrogen receptor alpha with protein kinase C alpha and c-Src in osteoblasts during differentiation. Bone 2004, 34:100-111. 10.1016/j.bone.2003.09.007, 14751567.
51. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 2007, 282:22278-22288. 10.1074/jbc.M611877200, 17535799.
52. Acconcia F, Ascenzi P, Fabozzi G, Visca P, Marino M. S-palmitoylation modulates human estrogen receptor-alpha functions. Biochem Biophys Res Commun 2004, 316:878-883. 10.1016/j.bbrc.2004.02.129, 15033483.
53. Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res 2012, 18:118-126. 10.1158/1078-0432.CCR-11-1236, 3263348, 21980134.
54. Levin ER. Elusive extranuclear estrogen receptors in breast cancer. Clin Cancer Res 2012, 18:6-8. 10.1158/1078-0432.CCR-11-2547, 3257555, 22215901.
55. O'Regan RM, Gajdos C, Dardes RC, De Los Reyes A, Park W, Rademaker AW, Jordan VC. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002, 94:274-283. 10.1093/jnci/94.4.274, 11854389.